Early caffeine therapy and clinical outcomes in extremely preterm infants

Journal of Perinatology

Volumn 33, Issue 2, 2013, Pages 134-140

  Patel, R M ^a,b   Leong, T ^c   Carlton, D P ^a,b   Vyas Read, S ^a,b,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^c EMORY UNIVERSITY   (United States)

^d Center for Developmental Lung Biology   (United States)

Author keywords

bronchopulmonary dysplasia; methylxanthine therapy; neonatal outcomes; patent ductus arteriosus

Indexed keywords

CAFFEINE;

ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; EARLY INTERVENTION; FEMALE; HUMAN; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; NEWBORN; NEWBORN DEATH; PATENT DUCTUS ARTERIOSUS; PREMATURITY; RETROSPECTIVE STUDY; RISK REDUCTION; TREATMENT OUTCOME;

BRONCHOPULMONARY DYSPLASIA; CAFFEINE; COHORT STUDIES; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DUCTUS ARTERIOSUS, PATENT; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HUMANS; INFANT, EXTREMELY PREMATURE; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; LOGISTIC MODELS; MALE; ODDS RATIO; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TERTIARY CARE CENTERS; TREATMENT OUTCOME;

EID: 84873277596     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2012.52     Document Type: Article

References (31)

1. Fanaroff AA, Stoll BJ, Wright LL, Carlo WA, Ehrenkranz RA, Stark AR et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007; 196(2): 147 e141-e148.
2. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010; 126(3): 443-456.
3. Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 2007; 357(19): 1946-1955.
4. Schmidt B, Roberts R, Millar D, Kirpalani H. Evidence-based neonatal drug therapy for prevention of bronchopulmonary dysplasia in very-low-birth-weight infants. Neonatology 2008; 93(4): 284-287.
5. Laughon MM, Smith PB, Bose C. Prevention of bronchopulmonary dysplasia. Semin Fetal Neonatal Med 2009; 14(6): 374-382.
6. Cotton RB, Stahlman MT, Bender HW, Graham TP, Catterton WZ, Kovar I. Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infants. J Pediatr 1978; 93(4): 647-651.
7. Brooks JM, Travadi JN, Patole SK, Doherty DA, Simmer K. Is surgical ligation of patent ductus arteriosus necessary? The Western Australian experience of conservative management. Arch Dis Child Fetal Neonatal Ed 2005; 90(3): F235-F239.
8. Marshall DD, Kotelchuck M, Young TE, Bose CL, Kruyer L, O'Shea TM. Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association. Pediatrics 1999; 104(6): 1345-1350.
9. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006; 354(20): 2112-2121.
10. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007; 357(19): 1893-1902.
11. Davis PG, Schmidt B, Roberts RS, Doyle LW, Asztalos E, Haslam R et al. Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. J Pediatr 2010; 156(3): 382-387.
12. Laughon MM, Langer JC, Bose CL, Smith PB, Ambalavanan N, Kennedy KA et al. Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants. Am J Respir Crit Care Med 2011; 183(12): 1715-1722.
13. Tyson JE, Parikh NA, Langer J, Green C, Higgins RD. Intensive care for extreme prematurity-moving beyond gestational age. N Engl J Med 2008; 358(16): 1672-1681.
14. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 2006; 117(6): 1979-1987.
15. Dukhovny D, Lorch SA, Schmidt B, Doyle LW, Kok JH, Roberts RS et al. Economic evaluation of caffeine for apnea of prematurity. Pediatrics 2011; 127(1): e146-e155.
16. Aranda JV, Turmen T, Davis J, Trippenbach T, Grondin D, Zinman R et al. Effect of caffeine on control of breathing in infantile apnea. J Pediatr 1983; 103(6): 975-978.
17. Davis JM, Bhutani VK, Stefano JL, Fox WW, Spitzer AR. Changes in pulmonary mechanics following caffeine administration in infants with bronchopulmonary dysplasia. Pediatr Pulmonol 1989; 6(1): 49-52.
18. Yoder B, Thomson M, Coalson J. Lung function in immature baboons with respiratory distress syndrome receiving early caffeine therapy: a pilot study. Acta Paediatr 2005; 94(1): 92-98.
19. Supinski GS, Deal Jr EC, Kelsen SG. The effects of caffeine and theophylline on diaphragm contractility. Am Rev Respir Dis 1984; 130(3): 429-433.
20. Li J, Li G, Hu JL, Fu XH, Zeng YJ, Zhou YG et al. Chronic or high dose acute caffeine treatment protects mice against oleic acid-induced acute lung injury via an adenosine A2A receptor-independent mechanism. Eur J Pharmacol 2011; 654(3): 295-303.
21. Oliveira-Junior IS, Pinheiro BV, Silva ID, Salomao R, Zollner RL, Beppu OS. Pentoxifylline decreases tumor necrosis factor and interleukin-1 during high tidal volume. Braz J Med Biol Res 2003; 36(10): 1349-1357.
22. Gillot I, Gouyon JB, Guignard JP. Renal effects of caffeine in preterm infants. Biol Neonate 1990; 58(3): 133-136.
23. Soloveychik V, Bin-Nun A, Ionchev A, Sriram S, Meadow W. Acute hemodynamic effects of caffeine administration in premature infants. J Perinatol 2009; 29(3): 205-208.
24. Blaustein MP, Golovina VA, Song H, Choate J, Lencesova L, Robinson SW et al. Organization of Ca2+ stores in vascular smooth muscle: functional implications. Novartis Found Symp 2002; 246: 125-137; discussion 137-141, 221-227.
25. Whorton AR, Collawn JB, Montgomery ME, Young SL, Kent RS. Arachidonic acid metabolism in cultured aortic endothelial cells. Effect of cAMP and 3-isobutyl-1- methylxanthine. Biochem Pharmacol 1985; 34(1): 119-123.
26. Clyman RI, Roman C. The effects of caffeine on the preterm sheep ductus arteriosus. Pediatr Res 2007; 62(2): 167-169.
27. Hamrick SE, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics 2010; 125(5): 1020-1030.
28. Henderson-Smart DJ, Davis PG. Prophylactic methylxanthines for endotracheal extubation in preterm infants. Cochrane Database Syst Rev 2010; (12): CD000139.
29. Hoecker C, Nelle M, Poeschl J, Beedgen B, Linderkamp O. Caffeine impairs cerebral and intestinal blood flow velocity in preterm infants. Pediatrics 2002; 109(5): 784-787.
30. Van Bel F, Van de Bor M, Stijnen T, Baan J, Ruys JH. Cerebral blood flow velocity changes in preterm infants after a single dose of indomethacin: duration of its effect. Pediatrics 1989; 84(5): 802-807.
31. Doyle LW, Cheong J, Hunt RW, Lee KJ, Thompson DK, Davis PG et al. Caffeine and brain development in very preterm infants. Ann Neurol 2010; 68(5): 734-742.